April 3, 2023 – Medcura, Inc., a life science and medical device company based in Riverdale, MD, is experiencing substantial growth in the BioHealth Capital Region. The company has developed a cutting-edge proprietary biosurgical technology demonstrating the rapid arrest of difficult-to-control surgical bleeding. This innovative technology offers the industry-best highly disruptive economics and has been tested in numerous challenging pre-clinical models. In addition to its versatility, the platform can be expanded into highly differentiated product solutions, as seen in Medcura’s emerging surgical and recently commercialized consumer product applications. Notably, the company’s products have garnered recognition for quickly stopping bleeding using naturally abundant and highly economical ingredients.
As Medcura continues to advance its science and technology, it has received support from BioHealth Innovation, Inc. (BHI), an innovation intermediary in the region that connects management, funding, and markets to translate market-relevant research into commercial success.
Colleen Nye, VP Surgical Product Development at Medcura, expressed appreciation for BHI’s assistance, stating, “Medcura has filled two quality positions. We really appreciate your support and inclusion of these on the BHI website. We were fortunate to find local candidates.”
The BioHealth Capital Region is a prime location for companies seeking opportunities to be founded, relocate, and grow. The region offers a thriving ecosystem with access to venture capital funding, employment opportunities, and a robust network of research institutions and industry experts. Medcura’s success in the BioHealth Capital Region is a testament to the region’s potential as a hub for innovation and growth in the biohealth sector.